ERC and ERT urge for full EU budget
Enlarge image


ERC and ERT urge for full EU budget

04.02.2013 - European company and research leaders have urged EU heads to greenlight €80bn for Horizon2020.

The joint letter of the European Round Table of Industrialists (ERT) and European Research Council (ERC) arrived some days before the EU Council will decide over the proposed €80m R&D budget of the EU innovation programme from 2014-2020. „We call on Europe’s leaders to approve the €80bn funding programme for research and innovation, Horizon 2020. This will lay the foundations for growth in Europe“, said ERC chief Helga Nowotny and ERT head Leif Johansson. The stakeholders warned that „any reduction in the funding to support excellent research will result in Europe having limited means to attract outstanding talent in a highly competitive global market.“ 

The EU heads will meet this week after negotiations of the EU Summit last November failed. A week before Council President Hermann van Rompuy’s initial budget proposal was withdrawn, 44 Nobel laureates had already warned in about the consequences of budget cuts to research and innovation. Over 100,000 Internet users supported their call not to slash the European Research Council (ERC) budget for excellent fundamental research. However, initial ideas discussed by the heads of EU Member States at the end of November foresaw cutting the €80bn innovation programme’s proposed budget by 12% (about €10bn) or more in favour of agriculture and structural funds.

This time, the research lobbyists try to make a stronger case: “Industry has long realised that one of its most precious assets is people“, stressed Nowotny and Johansson. „A continued supply of well-trained scientists and entrepreneurs is essential, especially for SMEs and start-up companies. Europe’s future can only be built on its brains.“



24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • SERODUS (N)2.67 NOK9.43%
  • VERONA PHARMA (UK)3.03 GBP8.21%


  • BIOFRONTERA (D)1.70 EUR-12.82%
  • DIAMYD MEDICAL -B- (S)9.30 SEK-11.43%
  • IMMUPHARMA (UK)23.00 GBP-6.12%


  • PLETHORA (UK)5.50 GBP83.3%
  • PROTHENA PLC (IE)70.04 USD42.0%
  • IMMUNICUM AB (S)43.10 SEK33.4%


  • EPIGENOMICS (D)1.85 EUR-61.4%
  • EVOCUTIS (UK)0.10 GBP-28.6%


  • KARO BIO (S)38.40 SEK5233.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.40 EUR269.7%


  • BIOTEST (D)15.25 EUR-80.8%
  • NEOVACS (F)0.72 EUR-78.1%

No liability assumed, Date: 24.11.2015